Launched in the UK in 2008, Xeomin® is the third botulinum toxin type A to be promoted in the UK. Xeomin® claims to be an innovative Botulinum type A formulation, in which the complexing proteins have been removed by an extensive purification process from the botulinum toxin complex. In contrast to the other commercially available preparations, Xeomin® contains the pure 150 kD neurotoxin.

It ...

Currently the number one non-surgical aesthetic treatment, Vistabel® is also the leading brand of botulinum toxin type – A in terms of documented clinical trials and practical use around the world.
Vistabel® was the first botulinum toxin to gain a cosmetic licence endorsing its use for glabellar lines and wrinkles. It is approved for this indication in the U.S. and around twelve other countries ...

Currently the number one non-surgical aesthetic treatment, Botox® is also the leading brand of botulinum toxin type – A in terms of documented clinical trials and practical use around the world.
Botox® was the first botulinum toxin to gain a cosmetic licence endorsing its use for glabellar lines and wrinkles. It is approved for this indication in the U.S. and around twelve other countries in the world, and was licenced ...

Azzalure®, botulinum toxin type A, has been available in the U.K. since the early 1990’s as the brand name Dysport®, which has licences for various indications in 67 countries worldwide, including the United Kingdom and many European markets.

It gained approval for cosmetic use in the UK in early 2009 and is marketed for this indication, with dosing specific to treat glabellar (frown) lines, under the brand name Azzalure®.

It is manufactured by ...